TY - JOUR T1 - Expression of Syndecan-1 in Chronic Liver Diseases: Correlation With Hepatic Fibrosis JF - In Vivo JO - In Vivo SP - 333 LP - 339 DO - 10.21873/invivo.12264 VL - 35 IS - 1 AU - ANTONIA CHARCHANTI AU - PANAGIOTIS KANAVAROS AU - EFTHYMIOS KONIARIS AU - AGAPI KATAKI AU - GEORGIOS GLANTZOUNIS AU - NIKI J. AGNANTIS AU - ANNA C. GOUSSIA Y1 - 2021/01/01 UR - http://iv.iiarjournals.org/content/35/1/333.abstract N2 - Background/Aim: The mechanisms underlying the contribution of the heparan sulfate proteoglycan syndecan-1 to liver tissue injury and to crucial biological processes, such as fibrogenesis, remain to be elucidated. Therefore, we investigated the immunohistochemical expression of syndecan-1 in chronic liver diseases (CLDs) and its probable role in hepatic fibrosis. Materials and Methods: Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections of biopsy material obtained from 128 patients diagnosed with CLDs. The correlation between syndecan-1 expression and the stage of fibrosis was investigated. Results: According to the severity of fibrosis, cases were categorized into three groups: early fibrosis; intermediate fibrosis; advanced fibrosis. Syndecan-1 expression was significantly enhanced in advanced fibrosis compared to early (p<0.012) and intermediate (p<0.003) fibrosis. Conclusion: In CLDs, syndecan-1 immunohisto-chemical overexpression was found to be positively correlated with the severity of fibrosis, suggesting its probable role in hepatic fibrogenesis. ER -